MINERVA IMAGING ApS - CVR: 34077746

2023, DKK

19.06.2024

Bruttoresultat

92.376'

Primær drift

23.472'

Årets resultat

17.180'

Aktiver

183''

Kortfristede aktiver

99.822'

Egenkapital

76.188'

Afkastningsgrad

13 %

Soliditetsgrad

42 %

Likviditetsgrad

161 %

Resultat

19.06.2024

Årsrapport	2023 19.06.2024	2022 30.06.2023	2021 30.05.2022	2020 30.06.2021
Nettoomsætning
Bruttoresultat	92.375.707	72.802.069	50.461.697	28.061.085
Resultat af primær drift	23.471.997	22.677.090	20.742.452	12.984.545
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0
Finansielle indtægter	46.924	8.620	86.209	63.250
Finansieringsomkostninger	-2.149.171	-1.736.186	-470.102	-289.521
Andre finansielle omkostninger	0	0	0	0
Resultat før skat	22.355.529	20.949.524	20.351.079	12.757.182
Resultat	17.179.529	16.212.180	15.721.167	10.262.982
Forslag til udbytte	-2.200.000	0	-1.000.000	0

Aktiver

19.06.2024

Årsrapport	2023 19.06.2024	2022 30.06.2023	2021 30.05.2022	2020 30.06.2021
Kortfristede varebeholdninger	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	98.542.272	94.538.027	38.591.978	15.661.363
Likvider	1.279.518	2.942.999	1.896.177	19.644.229
Kortfristede aktiver	99.821.790	97.481.026	40.488.155	35.305.592
Immaterielle aktiver og goodwill	0	0	0	0
Finansielle anlægsaktiver	26.056.717	19.598.993	18.606.007	8.124.611
Materielle aktiver	57.084.429	53.887.903	21.623.497	6.551.112
Langfristede aktiver	83.141.146	73.486.896	40.229.504	14.675.723
Aktiver	182.962.936	170.967.922	80.717.659	49.981.315

Aktiver

19.06.2024

Passiver

19.06.2024

Årsrapport	2023 19.06.2024	2022 30.06.2023	2021 30.05.2022	2020 30.06.2021
Forslag til udbytte	2.200.000	0	1.000.000	0
Egenkapital	76.188.390	53.918.666	38.989.771	23.268.604
Hensatte forpligtelser	5.616.000	440.000	992.674	78.810
Langfristet gæld til banker	840.356	1.113.071	0	0
Anden langfristet gæld		0	0	0
Leverandører af varer og tjenesteydelser	6.837.412	13.371.373	10.204.844	5.745.912
Kortfristede forpligtelser	62.039.588	77.394.866	40.735.214	26.633.901
Gældsforpligtelser	101.158.546	116.609.256	40.735.214	26.633.901
Forpligtelser	101.158.546	116.609.256	40.735.214	26.633.901
Passiver	182.962.936	170.967.922	80.717.659	49.981.315

Passiver

19.06.2024

Nøgletal

19.06.2024

Årsrapport	2023 19.06.2024	2022 30.06.2023	2021 30.05.2022	2020 30.06.2021
Afkastningsgrad	12,8 %	13,3 %	25,7 %	26,0 %
Dækningsgrad	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.
Egenkapitals-forretning	22,5 %	30,1 %	40,3 %	44,1 %
Payout-ratio	12,8 %	Na.	6,4 %	Na.
Gældsdæknings-nøgletal	1.092,1 %	1.306,1 %	4.412,3 %	4.484,8 %
Soliditestgrad	41,6 %	31,5 %	48,3 %	46,6 %
Likviditetsgrad	160,9 %	126,0 %	99,4 %	132,6 %

Resultat

19.06.2024

Gæld

19.06.2024

Årsrapport

19.06.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 19.06.2024)

Information om virksomhedens regnskabsklasse:The annual report for Minerva Imaging ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class C enterprises (medium sized enterprises).

Oplysning om pantsætninger og sikkerhedsstillelser:14. Charges and security For security for the company's and the group's bank commitments, the company has provided security in company assets representing a nominal value of 20.000 t.kr. This security comprises the assets below, stating the carrying amounts: DKK in thousands Trade receivables 32.227 Other fixtures, fittings, tools and equipment 16.591 Furthermore, the company has provided security in investments in group enterprises with a carrying amount of 22.726 t.kr., cf. note 6, for security for the group's bank commitment. The company has guaranteed the subsidiary, Bioadvice A/S, bank commitment. Fixtures, fittings, tools, and equipment representing a carrying amount of 40.493 t.kr.at 31 December 2023, cf. note 5, have been financed by means of finance leases. At 31 December 2023, this lease liability totals 44.362 t.kr. The company's total security for group enterprises amounts to a maximum of 123.362 t.kr.

Beretning

19.06.2024

Dato for ledelsens godkendelse af årsrapporten:2024-06-14

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Managing Director have approved the annual report of Minerva Imaging ApS for the financial year 1 January - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Description of key activities of the company Minerva Imaging’s vision is to become the leading contract research and contract development organization for targeted radionuclide therapy, enabling improved treatment regimens for cancer patients with a focus on the use of advanced animal models within oncology and cardiovascular diseases and in vivo molecular imaging for translational research and drug development. We aim to excel in delivering customized cancer radiopharmaceutical research and serve as an extended research team to our collaborators. We have built a global leading R&D platform for targeted radionuclide therapy and Contract Development and Manufacturing (CDMO) to enable integrated planning and faster execution of promising new radionuclide theragnostic projects in close collaboration with leading researchers, biotech, and pharmaceutical companies. Minerva is at the forefront of R&D in the theragnostic area. We are in a very fast-paced environment, where our researchers directly impact the advancement of new improved, and lifesaving drugs for seriously ill cancer patients. We have the ambition to make a difference for our clients, collaborating on advancing new treatment modalities for patients.